Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Sangen Decoction is a traditional Chinese medicine (TCM) formula composed of three natural medicinal herbs. It has been widely used in China for over 50 years as an adjuvant therapy in the treatment of gastrointestinal cancers, particularly colorectal cancer (CRC). The decoction is known for its ability to inhibit tumor growth and metastasis by suppressing epithelial-mesenchymal transition (EMT), reducing cell migration and invasion, and reversing chemoresistance to 5-fluorouracil. Mechanistically, it acts primarily through inhibition of the PI3K/AKT signaling pathway and modulation of EMT-related gene expression such as E-cadherin, N-cadherin, Slug, ZEB1. Preclinical studies have demonstrated that it can enhance apoptosis and repress proliferation in colon cancer cells[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Sangen Decoction.